mRNA Cancer Vaccines 2026: Moderna mRNA-4157 Hits 49% Recurrence Drop

Personalized mRNA cancer vaccines reached Phase 3 in 2026 for melanoma. Results, manufacturing pipeline, and what is next for lung and pancreatic.

Personalized Cancer Vaccines Arrive

Moderna mRNA-4157 (intismeran autogene) + Keytruda hit its Phase 3 endpoint in 2026, cutting melanoma recurrence 49% vs Keytruda alone.

How It Works

1. Tumor biopsy is sequenced
2. AI predicts up to 34 neoantigens unique to the patient
3. An mRNA vaccine encoding those neoantigens is manufactured in ~6 weeks
4. Six monthly doses train T cells to seek-and-destroy residual disease

Pipeline 2026

• NSCLC: Phase 2 readout Q4 (BioNTech BNT116)
• Pancreatic: Memorial Sloan Kettering personalized vaccine — 50% RFS at 3 years
• Renal cell carcinoma: Phase 2 expanded

Cost & Access

~$200K per course; Moderna is building a U.S. manufacturing campus in MA targeting 3-week turnaround.

Why This Matters

For the first time, immunotherapy can be truly individualized, sidestepping the immune-evasion tricks tumors use against checkpoint inhibitors alone.